Prognosis
Vaccine Maker Seeks Production Muscle in Coronavirus Fight
- Inovio targets 1 million doses this year if shot pans out
- ‘We’re running as fast as we can,’ CEO says in interview
Photographer: BSIP/Universal Images Group Editorial via Getty Images
This article is for subscribers only.
Inovio Pharmaceuticals Inc., one of a handful of companies racing to develop a coronavirus vaccine, is talking with larger drugmakers so it can deliver tens of millions of doses if successful.
The biotech company, based outside Philadelphia, aims to have at least 1 million doses available by the end of the year, then rely on bigger manufacturers to expand to as many as 50 million, Chief Executive Officer J. Joseph Kim said in an interview. That depends on clearing a number of hurdles, including studies in humans that are due to start by late spring or early summer, he said.